Disclosure of Editors' Financial Relationships

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Robert Freedman, M.D., reports no financial relationships with commercial interests.

David A. Lewis, M.D., currently receives investigator-initiated research support from Pfizer and serves as a consultant to Merck.

Robert Michels, M.D., reports no financial relationships with commercial interests.

Daniel S. Pine, M.D., reports no financial relationships with commercial interests.

A. John Rush, M.D., consulting fees from Akili, Brain Resource Inc., Compass Inc., CurbstoneConsultant LLC, Eli Lilly, Emmes Corp., John Peter Smith Healthcare, Liva-Nova, Mind Line, Sunovion, Takeda USA, Taj Medical, UT Southwestern Medical Center at Dallas; speaking fees from Liva-Nova and Sing-Health; and royalties from Guilford Press and UT Southwestern, Dallas (for the Inventory of Depressive symptoms and its derivatives such as the QIDS-C). He is a named co-inventor on two patents: U.S. Patent No. 7,795,033 (Methods to Predict the Outcome of Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS) and U.S. Patent No. 7,906,283 (Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S).

Susan K. Schultz, M.D., has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company.

Carol A. Tamminga, M.D., has received research support from Sunovion and travel funds from Autiphony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck.